跳转至内容
Merck

SML3230

Sigma-Aldrich

VU0360172 hydrochloride

≥98% (HPLC)

别名:

N-cyclobutyl-6-((3-fluorophenyl)ethynyl)nicotinamide hydrochloride

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C18H15FN2O · HCl
分子量:
330.78
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

儲存條件

desiccated

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear (warmed)

儲存溫度

−20°C

SMILES 字串

FC1=CC=CC(C#CC2=NC=C(C=C2)C(NC3CCC3)=O)=C1.Cl

InChI

1S/C18H15FN2O.ClH/c19-15-4-1-3-13(11-15)7-9-16-10-8-14(12-20-16)18(22)21-17-5-2-6-17;/h1,3-4,8,10-12,17H,2,5-6H2,(H,21,22);1H

InChI 密鑰

NBGAPTWZQXSEAA-UHFFFAOYSA-N

一般說明

VU0360172 is a potent (EC50 = 16.6 nM), systemically active positive allosteric modulator (PAM) of the metabotropic glutamate receptor subtype 5 (mGlu5). It is the first orally active mGlu5 PAM to be efficacious in an in vivo preclinical antipsychotic model, producing a dose-dependent reversal of amphetamine-induced hyperlocomotion. It was also found to reduce spontaneous absence seizures in WAG/Rij rats and to inhibit pain. Reduced spontaneous spike and wave discharges without impacting motor behavior in a rat model of absence epilepsy have been observed.

生化/生理作用

VU0360172 is a potent (EC50 = 16.6 nM), systemically active positive allosteric modulator (PAM) of the metabotropic glutamate receptor subtype 5 (mGlu5). It is the first orally active mGlu5 PAM to be efficacious in an in vivo preclinical antipsychotic model, producing a dose-dependent reversal of amphetamine-induced hyperlocomotion. It was also found to reduce absence seizures in WAG/Rij rats and to inhibit pain.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Potentiation of mGlu5 receptors with the novel enhancer, VU0360172, reduces spontaneous absence seizures in WAG/Rij rats
V. D'Amore, et al.
Neuropharmacology, 330-338 (2013)
Alice L Rodriguez et al.
Molecular pharmacology, 78(6), 1105-1123 (2010-10-07)
Modulators of metabotropic glutamate receptor subtype 5 (mGluR5) may provide novel treatments for multiple central nervous system (CNS) disorders, including anxiety and schizophrenia. Although compounds have been developed to better understand the physiological roles of mGluR5 and potential usefulness for

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门